[{"orgOrder":0,"company":"ImmunoBrain Checkpoint","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Funding","leadProduct":"IBC-Ab002","moa":"PD-L1","graph1":"Neurology","graph2":"Phase I","graph3":"ImmunoBrain Checkpoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmunoBrain Checkpoint \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoBrain Checkpoint \/ National Institute on Aging"},{"orgOrder":0,"company":"ImmunoBrain Checkpoint","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"IBC-Ab002","moa":"PD-L1","graph1":"Neurology","graph2":"Phase I","graph3":"ImmunoBrain Checkpoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmunoBrain Checkpoint \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoBrain Checkpoint \/ Alzheimer\u2019s Association"},{"orgOrder":0,"company":"ImmunoBrain Checkpoint","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IBC-Ab002","moa":"PD-L1","graph1":"Neurology","graph2":"Phase I","graph3":"ImmunoBrain Checkpoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmunoBrain Checkpoint \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoBrain Checkpoint \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciSparc \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The SCI-210 therapy combines cannabidiol and SciSparc's Palmitoylethanolamide, designed to reduce autism spectrum disorder (ASD) symptoms.

                          Product Name : SCI-210

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          December 31, 2024

                          Lead Product(s) : Cannabidiol,Palmitoylethanolamide

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS.

                          Product Name : SCI-110

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          August 23, 2024

                          Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The SCI-210 therapy combines cannabidiol and SciSparc's Palmitoylethanolamide, designed to reduce autism spectrum disorder (ASD) symptoms.

                          Product Name : SCI-210

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          August 19, 2024

                          Lead Product(s) : Cannabidiol,Palmitoylethanolamide

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : SCI-210 a combination of cannabidiol (CBD) and CannAmide™ (SciSparc’s Palmitoylethanolamide), which is being evaluated for the treatment of Autism Spectrum Disorder in children between 5 and 18 years.

                          Product Name : SCI-210

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          August 03, 2024

                          Lead Product(s) : Cannabidiol,Palmitoylethanolamide

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : SCI-210 (cannabidiol) is a combination of cannabidiol and CannAmide™ (SciSparc’s Palmitoylethanolamide), which is being evaluated in clinical trials for the treatment of autism spectrum disorder.

                          Product Name : SCI-210

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          January 29, 2024

                          Lead Product(s) : Cannabidiol,Cannamide

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : SCI-210 is a proprietary combination of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA, clinical trial will investigate SCI-210 in comparison to CBD monotherapy in treating ASD.

                          Product Name : SCI-210

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          September 29, 2023

                          Lead Product(s) : Cannabidiol,Cannamide

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : IBC-Ab002 is a novel, fully human anti-PD-L1 monoclonal antibody designed to harness the peripheral immune system to rewire brain/immune communication and protect the brain from functional loss in the patients with alzheimer's disease.

                          Product Name : IBC-Ab002

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 17, 2023

                          Lead Product(s) : IBC-Ab002

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The grant will phase 1 clinical trial to examine safety and activity of its proprietary antibody, IBC-Ab002, targeted to enhance the immune system and induce brain repair processes in individuals with Alzheimer’s disease.

                          Product Name : IBC-Ab002

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          January 09, 2020

                          Lead Product(s) : IBC-Ab002

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Alzheimer’s Association

                          Deal Size : $1.0 million

                          Deal Type : Funding

                          blank